SQZ Biotechnologies (NYSE:SQZ – Get Rating) shares have received a consensus rating of “buy” from the two rating agencies that currently cover the company, reports MarketBeat. Two research analysts have given the stock a buy rating. The average 12-month target price among brokers who have rated the stock over the past year is $28.50.
Separately, Chardan Capital began reporting on shares of SQZ Biotechnologies in a research report on Wednesday, May 25th. They put a “buy” rating on the company and a price target of $17.00.
In other news from SQZ Biotechnologies, Director Klavs F. Jensen acquired 14,326 shares of the company’s shares in a transaction on Wednesday, May 25. The stock was purchased at an average price of $3.52 per share for a total value of $50,427.52. Upon completion of the transaction, the Director now directly owns 353,309 shares of the Company, valued at $1,243,647.68. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC’s website. 18.00% of the shares are owned by company insiders.
A number of institutional investors and hedge funds have recently added to or reduced their holdings in SQZ. Citigroup Inc. increased its stake in SQZ Biotechnologies by 139.6% in the third quarter. Citigroup Inc. now owns 2,595 shares of the company’s stock valued at $37,000 after purchasing an additional 1,512 shares last quarter. The Royal Bank of Canada increased its stake in SQZ Biotechnologies by 96.2% in the third quarter. The Royal Bank of Canada now owns 3,059 shares of the company, valued at $44,000, after purchasing an additional 1,500 shares last quarter. Bangor Savings Bank bought a new position in SQZ Biotechnologies worth $99,000 during the fourth quarter. UBS Group AG increased its stake in SQZ Biotechnologies by 85.8% in the third quarter. UBS Group AG now owns 7,000 shares of the company, valued at $101,000, after purchasing an additional 3,233 shares last quarter. Finally, Metropolitan Life Insurance Co NY bought a new position in SQZ Biotechnologies valued at $104,000 during the third quarter. 66.56% of the shares are owned by institutional investors and hedge funds.
Shares of SQZ opened at $3.54 on Friday. The company has a market cap of $99.65 million, a price to earnings ratio of -1.34 and a beta of 3.71. The company’s 50-day simple moving average is $3.67 and its 200-day simple moving average is $6.23. SQZ Biotechnologies has a 1 year low of $2.73 and a 1 year high of $16.17.
SQZ Biotechnologies (NYSE:SQZ – Get Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.06). SQZ Biotechnologies had a negative net margin of 303.43% and a negative return on equity of 57.79%. As a group, equity analysts expect SQZ Biotechnologies to report fiscal year-to-date earnings per share of -2.87.
SQZ Biotechnologies company profile (received rating)
SQZ Biotechnologies Company, a clinical-stage biotechnology company, is developing cell therapies for patients suffering from cancer, autoimmune diseases, infectious diseases and other serious diseases. Its lead product candidate is SQZ-PBMC-HPV from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical , head and neck, anal, penile, vulva and vaginal cancer.
Receive News & Reviews for SQZ Biotechnologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for SQZ Biotechnologies and related companies with MarketBeat.com’s FREE daily email newsletter.